- Home
- NRT vs MDCX Comparison
NRT vs MDCX Comparison
Compare NRT & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NRT | MDCX |
|---|---|---|
| Founded | 1975 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 53.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRT | MDCX |
|---|---|---|
| Price | $6.30 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 56.6K | ★ 357.4K |
| Earning Date | 12-30-2025 | 11-14-2025 |
| Dividend Yield | ★ 12.90% | N/A |
| EPS Growth | ★ 24.05 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $6,184,173.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.71 | ★ N/A |
| Revenue Growth | ★ 18.55 | N/A |
| 52 Week Low | $3.88 | $1.68 |
| 52 Week High | $6.95 | $8.94 |
Technical Indicators
Market Signals| Indicator | NRT | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 41.15 |
| Support Level | $6.10 | $1.68 |
| Resistance Level | $6.40 | $2.03 |
| Average True Range (ATR) | 0.25 | 0.20 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 32.01 | 27.29 |
Price Performance
Historical ComparisonAbout NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.